The Public Policy Implications of the Abbott Split
This article was originally published in RPM Report
Abbott’s decision to spin-off proprietary pharmaceuticals as a stand-alone company is all about Wall Street: investors cheered the move for “unlocking value” by removing the giant shadow cast by Humira over the diversified base business. But it is also an important touchstone for all the key public policy themes playing out in the biopharma space after health care reform.
You may also be interested in...
How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.